Preparation method of rostafuroxin enteric-coated tablet

A technology of enteric-coated tablets and fuxin sausage, which is applied in the field of preparation of rotafoxin enteric-coated tablets, can solve problems such as complex mechanism, and achieve the effect of uniform granulation, simple and efficient granulation process, and uniform materials

Active Publication Date: 2018-06-01
ZHAOKE PHARMA HEFEI
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, recent studies have found that the mechanism is far more complex than originally thought

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of rostafuroxin enteric-coated tablet

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] (1) Prescription composition

[0025] prescription

Proportion in prescription (%)

role in prescription

Rotafusin

0.5

active ingredient

pregelatinized starch

55.0

filler

dextrin

15.0

filler

gelatin

8.0

Adhesive

Low-substituted hydroxypropyl cellulose

5.0

disintegrant

stearic acid

2.0

Surfactant

talcum powder

2

lubricant

purified water

40

solvent

Gastric film coating premix

3%

subcoat layer

Enteric Film Coating Premix

10%

Enteric layer

[0026] (2) Preparation process

[0027] 1) Sieving: Pass the various auxiliary materials through a 60-mesh sieve respectively, and set aside.

[0028] 2) Weighing: Weigh the pregelatinized starch, dextrin, and gelatin according to the prescription and mix them for later use.

[0029] 3) Dissolution: Prepare stearic acid aqueous solution with a concentration of 1% in an appropriat...

Embodiment 2

[0036] (1) Prescription composition

[0037] prescription

Proportion in prescription (%)

role in prescription

Rotafusin

0.50

active ingredient

lactose

91.0

filler

sodium alginate

4.0

Adhesive

Croscarmellose Sodium

1.0

disintegrant

Tween 80

0.5

Surfactant

Calcium stearate

0.3

lubricant

purified water

40

solvent

Gastric film coating premix

5%

subcoat layer

Enteric Film Coating Premix

15%

Enteric layer

[0038] (2) Preparation process

[0039] 1) Sieving: Pass the various auxiliary materials through a 100-mesh sieve respectively, and set aside.

[0040] 2) Weighing samples: Weigh lactose, sodium alginate, and croscarmellose sodium according to the prescription amount, and set aside.

[0041] 3) Dissolution: prepare a Tween 80 aqueous solution with a concentration of 5% in an appropriate container, and then add rotafucine into the 80 a...

Embodiment 3

[0048] (1) Prescription composition

[0049] prescription

Proportion in prescription (%)

role in prescription

Rotafusin

0.500

active ingredient

Mannitol

79.00

filler

microcrystalline cellulose

10.0

filler

Hydroxypropyl Cellulose

5.0

Adhesive

Crospovidone

3.0

disintegrant

Sodium dodecyl sulfate

1.0

Surfactant

Magnesium stearate

1.5

lubricant

purified water

40

solvent

Gastric film coating premix

3%

subcoat layer

Enteric Film Coating Premix

10%

Enteric layer

[0050] (2) Preparation process

[0051] 1) Sieving: Pass the various auxiliary materials through an 80-mesh sieve respectively, and set aside.

[0052] 2) Weighing samples: Weigh mannitol, microcrystalline cellulose, hydroxypropyl cellulose, and crospovidone (half the amount of the prescription) according to the prescription amount, and set aside.

[0053] 3) Disso...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a rostafuroxin enteric-coated tablet and a preparation method thereof. The preparation method comprises the following steps of (1) respectively screening 70% to 91% of filler,0.3% to 2% of lubricant, 4% to 8% of adhesive, 1% to 5% of disintegrant, and 0.5% to 2% of surfactant; mixing the filler and the adhesive to obtain a mixture; (2) adding pure water into the surfactantto prepare a surfactant water solution with concentration of 1% to 5%, adding 0.5% of rostafuroxin into the water solution, and dissolving by ultrasonic waves, so as to obtain a mixed solution; (3) atomizing and spraying the mixed solution obtained in step (2) into the mixture obtained in step (2), granulating the sprayed mixture, and drying, so as to obtain particles, wherein the percentage refers to the mass percentage of each component in the raw material; (4) granulating the particles obtained in step (3), adding the lubricant to uniformly mix, and tabletting, so as to obtain plain tablets; (5) coating the plain tablets for the second time, so as to obtain the enteric-coated tablet. The preparation method has the advantages that by adopting the preparation technique, the content of particle is uniform, the quality is stable, the loss amount is small, the technology process is simple, and the cost is effectively reduced.

Description

technical field [0001] The invention belongs to the field of medicines, and in particular relates to a preparation method of rotafoxine enteric-coated tablets. Background technique [0002] The main causes of hypertension are genetic factors, mental and environmental factors, age factors, lifestyle factors, drug effects and other diseases. About 60% of them have a family history of hypertension, so it is generally believed that it is caused by polygenic inheritance. If patients with high blood pressure cannot receive timely and effective treatment, they may increase the risk of heart failure, stroke and renal failure. [0003] The pathogenesis of hypertension is generally believed to be caused by sodium retention. However, recent studies have found that its mechanism is far more complex than originally thought. Many studies suggest that although other cardiac hormones, such as digoxin, are also present in human and animal plasma and tissues, only plasma endogenous ouabain...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/28A61K31/58A61K47/42A61K47/36A61K47/38A61P9/12
CPCA61K9/2054A61K9/2059A61K9/2063A61K9/2886A61K31/58
Inventor 陈倩欣张莹莹李小羿戴向荣殷雷凌娟
Owner ZHAOKE PHARMA HEFEI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products